Key result
Antithrombotic therapy in acute coronary syndrome yields similar benefits for men and women, though women face a consistently higher risk of bleeding and suboptimal medication dosing.
Why the study?
Are there sex-specific differences in the benefits and risks of antithrombotic therapy in patients with acute coronary syndrome?
Are there sex-specific differences in the benefits and risks of antithrombotic therapy in patients with acute coronary syndrome?
This review highlights that while women with ACS derive similar benefits from antithrombotic therapy as men, they face higher bleeding risks and disparities in dosing and adherence, necessitating sex-specific management strategies.
Answers are grounded in this paper and cite their sources.
May warrant closer bleeding monitoring for women on ACS antithrombotics; leaves open optimal sex-specific dosing strategies.
Over the past decade, more men than women have shown improved outcomes from antithrombotic therapies after acute coronary syndrome (ACS), which raises the question of whether there are sex-specific differences in treatment patterns and response to therapy. Differences in presenting clinical characteristics, pathophysiologic profile, and disparities in treatment may contribute to this outcomes discrepancy. Analyses of large trials and registry data suggest that male and female ACS patients experience similar benefits from antithrombotic therapy without significant difference in treatment utilization rates, yet women are consistently at higher risk of bleeding than men. Bleeding may result in antithrombotic treatment disruption, which increases the risk of long-term thrombotic events. Additionally, female ACS patients are more likely to receive suboptimal medication dosing and have lower rates of long-term medication adherence. These differences have significant clinical implications for women, indicating the need for strategies that will optimize initial treatment and long-term management attuned to these recognized sex-specific gaps.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) conducted a review in Acute coronary syndrome. Antithrombotic therapy was evaluated. Antithrombotic therapy in acute coronary syndrome yields similar benefits for men and women, though women face a consistently higher risk of bleeding and suboptimal medication dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: